LRP1 and neoplasm: Clinical trials (NCT01967810, NCT01480583, NCT02048059, and NCT01497665), such as those investigating ANG1005 and GRN1005, have explored LRP1-targeting therapeutics, where paclitaxel molecules are covalently linked to Angiopep-2 to enhance BBB penetration and tumor uptake while circumventing P-gp-mediated drug efflux (Table 7) [169,170].